Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 380

1.

Aggressive angiomyxoma of pelvic parts exhibits oestrogen and progesterone receptor positivity.

McCluggage WG, Patterson A, Maxwell P.

J Clin Pathol. 2000 Aug;53(8):603-5.

2.
3.

Aggressive angiomyxoma of the vulva: expression of estroprogestinic receptors and follow-up.

De Salvia D, Fais GF, Lauri F, Brotto M, Petrillo G, Salmaso R.

Clin Exp Obstet Gynecol. 1998;25(4):141-3.

PMID:
9987573
4.

Aggressive angiomyxoma: reappraisal of its relationship to angiomyofibroblastoma in a series of 16 cases.

Granter SR, Nucci MR, Fletcher CD.

Histopathology. 1997 Jan;30(1):3-10.

PMID:
9023551
5.

Estrogen and progesterone receptors in normal and malignant vulvar tissue.

Omsjö IH, Wright PB, Börmer OP.

Gynecol Obstet Invest. 1984;17(6):281-3.

PMID:
6745735
6.
7.

Aggressive angiomyxoma: a clinicopathologic study of 29 female patients.

Fetsch JF, Laskin WB, Lefkowitz M, Kindblom LG, Meis-Kindblom JM.

Cancer. 1996 Jul 1;78(1):79-90.

8.

Aggressive angiomyxoma of the vulva: Dramatic response to gonadotropin-releasing hormone agonist therapy.

McCluggage WG, Jamieson T, Dobbs SP, Grey A.

Gynecol Oncol. 2006 Mar;100(3):623-5. Epub 2005 Oct 21.

PMID:
16246403
9.

Aggressive angiomyxoma presenting as a vulval polyp.

Srinivasan R, Mohapatra N, Malhotra S, Rao SK.

Indian J Cancer. 2007 Apr-Jun;44(2):87-9.

10.

Aggressive angiomyxoma of pelvic soft parts: a clinicopathologic study of nine cases.

Bégin LR, Clement PB, Kirk ME, Jothy S, McCaughey WT, Ferenczy A.

Hum Pathol. 1985 Jun;16(6):621-8.

PMID:
3997139
11.

Aggressive angiomyxoma of the pelvioperineal region. Immunohistological and ultrastructural study of seven cases.

Skálová A, Michal M, Husek K, Zámecník M, Leivo I.

Am J Dermatopathol. 1993 Oct;15(5):446-51.

PMID:
8238780
12.

Angiomyofibroblastoma of the vulva. A benign neoplasm distinct from aggressive angiomyxoma.

Fletcher CD, Tsang WY, Fisher C, Lee KC, Chan JK.

Am J Surg Pathol. 1992 Apr;16(4):373-82.

PMID:
1314521
13.

HMGA2 is a sensitive but not specific immunohistochemical marker of vulvovaginal aggressive angiomyxoma.

McCluggage WG, Connolly L, McBride HA.

Am J Surg Pathol. 2010 Jul;34(7):1037-42. doi: 10.1097/PAS.0b013e3181e32a11.

PMID:
20551826
14.

Aggressive angiomyxoma of the female genital tract: a clinicopathologic and immunohistochemical study of 12 cases.

Amezcua CA, Begley SJ, Mata N, Felix JC, Ballard CA.

Int J Gynecol Cancer. 2005 Jan-Feb;15(1):140-5.

PMID:
15670309
16.

Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.

Francis G, Beadle G, Thomas S, Mengersen K, Stein S.

Pathology. 2006 Oct;38(5):391-8.

PMID:
17008275
17.

Immunohistochemical assessment of steroid hormone receptors in tissues of the anal canal. Implications for anal incontinence?

Franz HB, Wendler D, Oettling G.

Acta Obstet Gynecol Scand. 1996 Nov;75(10):892-5.

PMID:
9003088
18.

Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.

Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.

Oncol Rep. 2007 Nov;18(5):1051-9.

PMID:
17914554
20.

Estrogen and progesterone receptor sites in malignancies of the uterine cervix, vagina, and vulva.

Ford LC, Berek JS, Lagasse LD, Hacker NF, Heins YL, DeLange RJ.

Gynecol Oncol. 1983 Feb;15(1):27-31.

PMID:
6822366

Supplemental Content

Support Center